LUCD

Lucid is a commercial-stage, one-product story (EsoGuard/EsoCheck for esophageal precancer) whose economics do not yet work. FY2025 revenue was just $4.71M, up a soft 8.3% YoY, against a net loss of $58.0M that widened 27.4% — a net margin of -1,232.7% and an operating margin of -1,054.8%. Operating cash flow was -$46.5M. The filing removes any ambiguity: management 'concluded there is substantial doubt of our ability to continue as a going concern' and the auditor's report carries a matching explanatory paragraph. Reported cash was $22.4M (FY2024), which does not cover even one more year of burn at the current rate, so additional financing is not optional — it is required to keep the doors open.

That financing is coming out of shareholders' hides. Shares outstanding grew 95.0% YoY to 177M, and the 10-K spells out the mechanism: 'we have issued a significant amount of convertible securities under which we expect to issue a correspondingly significant amount of shares... upon conversion,' all of which 'would dilute the equity interest of our stockholders.' The company also flags that it must fund its own needs while its parent, PAVmed, 'requires its own additional capital funding.' Stockholders' equity is a thin $10.9M supporting a -$274M accumulated deficit, with liabilities/equity at 2.70x — a balance sheet propped up only by serial equity raises.